BOULDER, Colo., May 8, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare conference in New York City. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Event:Bank of America Merrill Lynch Healthcare ConferenceDate:Thursday, May 16, 2013Time:11:20 a.m. PDT Location:Encore at the Wynn, Las Vegas, NVEvent:UBS Global Healthcare ConferenceDate:Tuesday, May 21, 2013Time:8:30 a.m. EDT Location:Sheraton New York Hotel, NYC, NYAbout Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013. In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013. AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib (an Array-invented drug) in non-small cell lung cancer and thyroid cancer during the second half of 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche). For more information on Array, please go to www.arraybiopharma.com.
Tricia HaugetoArray BioPharma Inc.firstname.lastname@example.org
|SOURCE Array BioPharma Inc.|
Copyright©2012 PR Newswire.
All rights reserved